News & Updates
Filter by Specialty:
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.
First-line pembrolizumab feasible for BRAF V600–mutant melanoma
10 Nov 2022
AF does not reduce dapagliflozin efficacy in HF patients
The presence of atrial fibrillation (AF) at baseline does not appear to modify the benefits of dapagliflozin, compared with placebo, on symptoms and clinical events in patients with heart failure and preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), according to a study.
AF does not reduce dapagliflozin efficacy in HF patients
10 Nov 2022
COVID-19 vaccine for children below 5 years: most parents still hesitant
Widespread hesitancy around COVID-19 vaccination in children below 5 years does exist, even among parents showing preference for vaccinating their child in this age group, a US study suggests.
COVID-19 vaccine for children below 5 years: most parents still hesitant
10 Nov 2022
Nursing interventions boost sexual QoL of breast cancer patients
Nursing interventions such as psychological and educational assistance help improve the sexual quality of life (QoL) among patients with breast cancer, reports a recent study.
